Kidney Fat in Type 2 Diabetes and the Effects of Ezetimibe

NCT ID: NCT04589351

Last Updated: 2022-01-18

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-10-01
• Study Completion Date: 2022-05-31

Brief Summary

In this study, we seek to explore the importance of fat accumulation in the kidneys in relation to diabetic kidney disease (DKD). To do this, we conduct an intervention trial in individuals with type 2 diabetes (T2D) and DKD where we investigate whether the inhibition of intestinal cholesterol absorption with ezetimibe affects albuminuria (a strong risk factor for diabetic complications) and kidney fat accumulation. At the same time and to confirm that kidney fat accumulation is, in fact, abnormal in T2D and DKD, we conduct a cross-sectional study in which we compare kidney fat accumulation in participants at baseline from the intervention trial with a group of individuals with T2D and no DKD and a group of healthy individuals.

Detailed Description

Objective:

1. To compare cross-sectionally the fractions of kidney lipid between controls, individuals with type 2 diabetes and no diabetic kidney disease and individuals with type 2 diabetes and non-severe diabetic kidney disease.

2. To assess by intervention trial whether ezetimibe reduces albuminuria and kidney parenchymal triglyceride fraction in individuals with type 2 diabetes and non-severe diabetic kidney disease.

Design:

1. Cross-sectional study on 30 controls, 30 individuals with type 2 diabetes and no diabetic kidney disease and 60 individuals with type 2 diabetes and non-severe diabetic kidney disease.

2. Single-center, randomized, double-blinded, placebo-controlled and parallel intervention trial in 60 individuals with type 2 diabetes and non-severe diabetic kidney disease Comparative treatment regime: Ezetimibe 10mg per day versus placebo for 16 weeks

Primary endpoint in cross-sectional study:

• Kidney parenchymal triglyceride fraction (estimated by magnetic resonance spectroscopy)

Primary endpoint in intervention trial:

• Urinary albumin creatinine ratio

Secondary endpoint in intervention trial:

• Kidney parenchymal triglyceride fraction (estimated by magnetic resonance spectroscopy)

Main eligibility criteria for control group (cross-sectional study alone):

• Age 40-75 years

• No diabetes mellitus

• No kidney disease or urinary albumin creatinine ratio ≥ 30mg/g

• No contraindication to examination by magnetic resonance

Main eligibility criteria for group of individuals with type 2 diabetes and no diabetic kidney disease (cross-sectional study alone):

• Age 40-75 years
• Type 2 diabetes
• No kidney disease or urinary albumin creatinine ratio ≥ 30mg/g
• No contraindication to examination by magnetic resonance

Main eligibility criteria for group of individuals with type 2 diabetes and non-severe diabetic kidney disease (intervention trial):

• Age 40-75 years
• Type 2 diabetes
• Estimated glomerular filtration rate ≥30ml/min/1,73m2
• Urinary albumin creatinine ratio ≥ 30mg/g
• No contraindication to examination by magnetic resonance

Recruitment

• Controls are recruited via announcements on relevant websites and, if necessary, in newspapers
• Individuals with type 2 diabetes are primarily recruited from the ambulatory at Steno Diabetes Center Copenhagen

Conditions

Diabetes Mellitus, Type 2; Diabetic Kidney Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Ezetimibe

One treatment period of 16 weeks with1 capsule of ezetimibe 10mg per day, as add-on to standard care.

Group Type: ACTIVE_COMPARATOR

Ezetimibe 10mg

Intervention Type: DRUG

Ezetimibe is a cholesterol absorption inhibitor with marketing approval. The recommended dose as per label is 10mg once a day.

Placebo

One treatment period of 16 weeks with 1 capsule of matching placebo per day, as add-on to standard care.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Matching placebo

Interventions

Ezetimibe 10mg

Ezetimibe is a cholesterol absorption inhibitor with marketing approval. The recommended dose as per label is 10mg once a day.

Intervention Type: DRUG

Placebo

Matching placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Age ≥ 40 and ≤ 75 years
• T2D (World Health Organization criteria)
• eGFR ≥ 30ml/min/1,73m2 at screening
• Persistent UACR ≥ 30mg/g (in more than two out of three valid measurements over a minimum of three months)
• LDL > 1.5mmol/L at screening
• Ability to communicate with the investigator and give informed consent

• Age ≥ 40 and ≤ 75 years
• eGFR ≥60ml/min/1,73m2 at screening
• Ability to communicate with the investigator and give informed consent

• Age ≥ 40 and ≤ 75 years
• T2D (World Health Organization criteria)
• eGFR ≥60ml/min/1,73m2 at screening
• Ability to communicate with the Investigator and give informed consent

Exclusion Criteria

• Chronic kidney disease primarily ascribed to other causes than diabetes
• Acute kidney disease within 3 months
• No UACR ≥ 3000mg/g in history
• Current or recent (within 3 months) treatment with ezetimibe
• Initiation or adjustment in dosage within 1 month of an angiotensin-converting enzyme (ACE) inhibitor, angiotensin II receptor blocker (ARB), glucagon-like peptide-1 receptor (GLP-1RA) agonists, sodium-glucose cotransporter 2 (SGLT-2) inhibitors or anti-dyslipidemia drug, e.g. a statin
• Any contraindication to MR-examination (e.g. magnetic foreign body that cannot easily be removed from the body prior to the examination, claustrophobia or body size not compatible with the scanner)
• Intolerance to trial drug components
• Any previous major organ transplantation
• Elective major surgery during the trial
• Pregnancy, planned pregnancy or breastfeeding during the trial
• Insufficient contraception during the trial in women of childbearing potential
• Severe alcohol consumption or abuse of recreational drugs
• Moderate to severe liver failure (Child Pugh 7-15)
• Any surgical or medical condition which can be expected to significantly alter the absorption of the trial drug (e.g. major gastrointestinal tract surgery or inflammatory bowel disease)
• Recent (within 30 days or 5-half-lives, whichever is longer) or current participation in another clinical study in which an investigational medicinal product or device has been received
• Any medical condition or history thereof or any deviation from normal laboratory values that, in the opinion of the investigator, clinically contraindicates or hinders the completion of the trial
• Any reason for suspecting a considerable lack of compliance to the trial

• Any major chronic disease, e.g. diabetes mellitus, chronic kidney disease, ischemic heart disease, chronic obstructive pulmonary disease (this criterium does not include conditions that may be considered risk factors for chronic diseases, e.g. essential hypertension, primary hypercholesterolemia)
• Acute kidney disease within 3 months
• History of persistent UACR ≥ 30mg/g (in more than two out of three valid measurements over a minimum of three months including those at screening) or a previous diagnosis of micro- or macroalbuminuria
• Current or recent (within 3 months) treatment with ezetimibe
• Any contraindication to an MR-examination (e.g. magnetic foreign body that cannot easily be removed from the body prior to the examination or claustrophobia)
• Any previous major organ transplantation
• Elective major surgery during the study
• Pregnancy, planned pregnancy or breastfeeding during the study
• Severe alcohol consumption or abuse of recreational drugs
• Moderate to severe liver failure (Child Pugh 7-15)
• Recent (within 30 days or 5-half-lives, whichever is longer) or current participation in another clinical study in which an investigational medicinal product or device has been received
• Any medical condition or history thereof or any deviation from normal laboratory values that, in the opinion of the investigator, clinically contraindicates or hinders the completion of the study
• Any reason for suspecting a considerable lack of compliance to the study

• Any chronic kidney disease
• Acute kidney disease within 3 months
• History of persistent UACR ≥ 30mg/g (in more than two out of three valid measurements over a minimum of three months including those at screening) or a previous diagnosis of micro- or macroalbuminuria
• Current or recent (within 3 months) treatment with ezetimibe
• Any contraindication to an MR-examination (e.g. magnetic foreign body that cannot easily be removed from the body prior to the examination or claustrophobia)
• Any previous major organ transplantation
• Elective major surgery during the study
• Pregnancy, planned pregnancy or breastfeeding during the study
• Severe alcohol consumption or abuse of recreational drugs
• Moderate to severe liver failure (Child Pugh 7-15)
• Recent (within 30 days or 5-half-lives, whichever is longer) or current participation in another clinical study in which an investigational medicinal product or device has been received
• Any medical condition or history thereof or any deviation from normal laboratory values that, in the opinion of the investigator, clinically contraindicates or hinders the completion of the study procedures
• Any reason for suspecting a considerable lack of compliance to the study

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Department of Clinical Physiology, Nuclear Medicine and PET at Rigshospitalet Glostrup, Valdemar Hansens Vej 1-23, 2600 Glostrup, Denmark

UNKNOWN

Sponsor Role: collaborator

Aalborg University Hospital

OTHER

Sponsor Role: collaborator

Capital Region's Pharmacy (Region Hovedstadens Apotek), Marielundvej 25, 2730 Herlev, Denmark

UNKNOWN

Sponsor Role: collaborator

Alessia Fornoni, MD PhD, Professor of Medicine, Chief, Katz Family Division of Nephrology and Hypertension

UNKNOWN

Sponsor Role: collaborator

Steno Diabetes Center Copenhagen

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Steno Diabetes Center Copenhagen

Gentofte Municipality, Capital Region, Denmark

Countries

Denmark

Other Identifiers

2020-001155-40

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

16032020

Identifier Type: -

Identifier Source: org_study_id